BMO Capital Markets Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutic (NASDAQ: YMABGet a rating) saw its price target lowered by equity analysts at BMO Capital Markets from $29.00 to $12.00 in a report on Tuesday, Fly reports. The BMO Capital Markets target price indicates a potential upside of 232.41% from the company’s current price.

A number of other research firms have also weighed in on YMAB recently. Morgan Stanley cut its price target on shares of Y-mAbs Therapeutics from $17.00 to $8.00 and set an “equal weight” rating on the stock in a report released Monday. Wedbush downgraded shares of Y-mAbs Therapeutics from an “outperforming” rating to a “neutral” rating and lowered its price target for the company from $21.00 to $6.00 in a research report released on Monday. . Guggenheim lowered its price target on shares of Y-mAbs Therapeutics from $26.00 to $18.00 in a research report on Monday. JPMorgan Chase & Co. downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underweight” rating and lowered its price target for the company from $16.00 to $7.00 in a research report published on Monday. Finally, Kempen & Co downgraded shares of Y-mAbs Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. One equity research analyst rated the stock with a sell rating, three issued a hold rating and four gave the company’s stock a buy rating. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Hold” and an average target price of $15.50.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $3.61 on Tuesday. The stock has a market capitalization of $157.83 million, a PE ratio of -1.17 and a beta of 1.12. Y-mAbs Therapeutics has a 1 year minimum of $3.54 and a 1 year maximum of $28.50. The company’s 50-day simple moving average is $14.35 and its 200-day simple moving average is $14.04.

Y-mAbs Therapeutic (NASDAQ: YMABGet a rating) last released its results on Monday, August 8. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.26). The company posted revenue of $10.80 million in the quarter, compared to analyst estimates of $11.22 million. Y-mAbs Therapeutics had a negative net margin of 338.68% and a negative return on equity of 79.40%. The company’s revenue fell 1.4% compared to the same quarter last year. During the same period last year, the company achieved EPS of ($0.53). On average, sell-side analysts predict Y-mAbs Therapeutics to post -1.88 earnings per share for the current year.

Institutional entries and exits

Several institutional investors have recently increased or reduced their stake in YMAB. BlackRock Inc. increased its stake in Y-mAbs Therapeutics by 6.4% in Q1. BlackRock Inc. now owns 2,945,094 shares of the company worth $34,986,000 after acquiring an additional 177,734 shares during the period. Polar Capital Holdings Plc increased its stake in Y-mAbs Therapeutics by 108.9% in Q1. Polar Capital Holdings Plc now owns 2,877,671 shares in the company worth $34,187,000 after acquiring an additional 1,500,000 shares during the period. State Street Corp increased its stake in Y-mAbs Therapeutics by 58.5% in the first quarter. State Street Corp now owns 2,308,782 shares of the company worth $27,428,000 after acquiring an additional 852,112 shares during the period. Walleye Capital LLC bought a new position in Y-mAbs Therapeutics in Q2 for a value of approximately $6,296,000. Finally, Bank of America Corp DE increased its position in shares of Y-mAbs Therapeutics by 386.8% in the 1st quarter. Bank of America Corp DE now owns 398,823 shares of the company valued at $4,738,000 after buying an additional 316,898 shares last quarter. Institutional investors and hedge funds hold 56.70% of the company’s shares.

Company Profile Y-mAbs Therapeutics

(Get a rating)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, is focused on the development and commercialization of novel antibody-based therapeutics for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Read more

The Fly logo

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ: YMAB)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Y-mAbs Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and Y-mAbs Therapeutics didn’t make the list.

While Y-mAbs Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here